Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 10/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25286887 | 0.90 | HRH3 (0.46) | EPHX2RAF1BRAFUSP30 | |
| SCHEMBL25287926 | 0.90 | HRH3 (0.46) | EPHX2RAF1BRAFUSP30 | |
| SCHEMBL25289169 | 0.84 | HRH3 (0.38) | GPR119USP30 | |
| SCHEMBL8534571 | 0.83 | LPL (0.41) | — | |
| SCHEMBL29245339 | 0.82 | PRKAA2 (0.42) | GPR119PRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL29245338 | 0.82 | PRKAA2 (0.42) | GPR119PRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL8609796 | 0.76 | LPL (0.41) | EPHX2 | |
| SCHEMBL25245422 | 0.76 | USP30 (0.48) | GPR119PRKAA2EPHX2RAF1BRAF | |
| SCHEMBL31362178 | 0.76 | USP30 (0.48) | GPR119PRKAA2EPHX2RAF1BRAF | |
| SCHEMBL25283897 | 0.74 | HRH3 (0.41) | EPHX2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | GPR119 2856/4885PRKAA2 135/4885PRKAB2 55/4885 |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | GPR119 3057/4885PRKAA2 129/4885PRKAB2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.